文献速递肿瘤 PET/CT神经核医学

TGF-β激活剂体内追踪:68Ga标记环状RGD八肽三聚体68Ga-Triveoctin对αvβ8整合素的敏感PET显像

Tracking a TGF-β activator in vivo: sensitive PET imaging of αvβ8-integrin with the Ga-68-labeled cyclic RGD octapeptide trimer Ga-68-Triveoctin.
PubMed 文献 · EJNMMI Res · 2020-10-31

本研究合成68Ga标记的环状RGD八肽三聚体68Ga-Triveoctin,在MeWo黑色素瘤荷瘤SCID小鼠中行PET与离体生物分布,并在一名人体受试者中行单次注射后25、45、90分钟PET/CT。三聚体对αvβ8整合素亲和力较单体高6.7倍(IC50 5.7 vs 38 nM),小鼠肿瘤摄取更高(1.9 vs 1.0 %IA/g),人体生物分布良好,提示其有临床显像αvβ8整合素表达的潜力。

要点

  • 68Ga-Triveoctin三聚体对αvβ8整合素亲和力较单体高6.7倍(IC50 5.7 vs 38 nM)。
  • 小鼠肿瘤摄取1.9 %IA/g,阻断后降至0.25 %IA/g,非靶组织摄取低(<0.4 %IA/g)。
  • 人体PET显示肾脏摄取低于小鼠,腹腔干和脉络丛有显著摄取(SUVmean 6.1和9.7,90分钟)。

核心结论

  • 68Ga-Triveoctin可在小鼠肿瘤移植瘤中敏感显像αvβ8整合素表达,人体PET证实其生物分布良好,提示有临床应用的潜力。

研究设计与样本

  • 研究合成单体与三聚体环状RGD八肽偶联物,经点击化学(CuAAC)制备、68Ga标记,在MeWo人黑色素瘤SCID小鼠模型中行PET和离体生物分布,并用β8免疫组化检测小鼠组织αvβ8整合素表达。
  • 一名人体受试者单次注射173 MBq 68Ga-Triveoctin,于注射后25、45、90分钟行三次PET/CT扫描。

主要发现

  • 三聚体68Ga-Triveoctin对αvβ8整合素的亲和力较单体高6.7倍(IC50分别为5.7 nM和38 nM)。
  • 小鼠生物分布显示三聚体肿瘤摄取高于单体(1.9 vs 1.0 %IA/g),阻断后两者基线相似(均为0.25 %IA/g)。
  • 免疫组化显示肿瘤β8表达中等,多数器官和组织β8阴性,非靶组织摄取低(<0.4 %IA/g)。
  • 68Ga-Triveoctin因亲水性(log D = -3.1)经肾排泄,小鼠肿瘤/血、肿瘤/肝、肿瘤/肌肉比值分别为6.7、6.8、29。
  • 小鼠肾脏摄取高(肾/血和肾/肌肉比值分别为126和505),但人体PET相应比值较低(分别为15和30),且人体90分钟时腹腔干和脉络丛SUVmean分别为6.1和9.7。

临床怎么用

  • 68Ga-Triveoctin有望用于临床PET显像αvβ8整合素表达,辅助评估TGF-β相关肿瘤进程并支持TGF-β靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: As a major activator of transforming growth factor β (TGF-β), the RGD receptor αvβ8-integrin is involved in pathogenic processes related to TGF-β dysregulation, such as tumor growth, invasion, and radiochemoresistance, metastasis and tumor cell stemness, as well as epithelial-mesenchymal transition. The novel positron emission tomography (PET) radiopharmaceutical Ga-68-Triveoctin for in vivo mapping of αvβ8-integrin expression might enhance the prognosis of certain tumor entities, as well as support and augment TGF-β-targeted therapeutic approaches. METHODS: Monomeric and trimeric conjugates of cyclo(GLRGDLp(NMe)K(pent-4-ynoic amide)) were synthesized by click chemistry (CuAAC), labeled with Ga-68, and evaluated in MeWo (human melanoma) xenografted SCID mice by means of PET and ex-vivo biodistribution. αvβ8-integrin expression in murine tissues was determined by β8-IHC. A human subject received a single injection of 173 MBq of Ga-68-Triveoctin and underwent 3 subsequent PET/CT scans at 25, 45, and 90 min p.i.. RESULTS: The trimer Ga-68-Triveoctin exhibits a 6.7-fold higher αvβ8-integrin affinity than the monomer (IC50 of 5.7 vs. 38 nM, respectively). Accordingly, biodistribution showed a higher tumor uptake (1.9 vs. 1.0%IA/g, respectively) but a similar baseline upon blockade (0.25%IA/g for both). IHC showed an intermediate β8-expression in the tumor while most organs and tissues were found β8-negative. Low non-target tissue uptakes (< 0.4%IA/g) confirmed a low degree of unspecific binding. Due to its hydrophilicity (log D = - 3.1), Ga-68-Triveoctin is excreted renally and shows favorable tumor/tissue ratios in mice (t/blood: 6.7; t/liver: 6.8; t/muscle: 29). A high kidney uptake in mice (kidney-to-blood and -to-muscle ratios of 126 and 505, respectively) is not reflected by human PET (corresponding values are 15 and 30, respectively), which furthermore showed notable uptakes in coeliac and choroid plexus (SUVmean 6.1 and 9.7, respectively, 90 min p.i.). CONCLUSION: Ga-68-Triveoctin enables sensitive in-vivo imaging αvβ8-integrin expression in murine tumor xenografts. PET in a human subject confirmed a favorable biodistribution, underscoring the potential of Ga-68-Triveoctin for mapping of αvβ8-integrin expression in a clinical setting.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Quigley NG, Steiger K, Richter F, et al. Tracking a TGF-β activator in vivo: sensitive PET imaging of αvβ8-integrin with the Ga-68-labeled cyclic RGD octapeptide trimer Ga-68-Triveoctin. EJNMMI Res. 2020. PMID: 33128636. doi:10.1186/s13550-020-00706-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。